Welcome to our dedicated page for Aclaris Therapeutics news (Ticker: ACRS), a resource for investors and traders seeking the latest updates and insights on Aclaris Therapeutics stock.
Aclaris Therapeutics develops novel product candidates for immuno-inflammatory diseases as a clinical-stage biopharmaceutical company. News about ACRS centers on clinical and corporate updates for ATI-052, an investigational anti-TSLP/IL-4Rα bispecific antibody; ATI-2138, an oral ITK/JAK3 inhibitor; and bosakitug (ATI-045), an anti-TSLP antibody program. Recurring updates include trial results and medical-meeting presentations in dermatology and inflammatory disease, development work in atopic dermatitis, lichen planus and asthma, financial results, R&D spending, royalty revenue from license agreements and healthcare conference presentations.
Aclaris Therapeutics, a clinical-stage biopharmaceutical company listed on NASDAQ under the symbol ACRS, announced their participation in two upcoming investor conferences. Dr. Neal Walker, President and CEO, will present at the H.C. Wainwright 23rd Annual Global Investment Conference on September 13, 2021, and at the 2021 Cantor Virtual Global Healthcare Conference on September 27, 2021. Both events will include opportunities for virtual one-on-one meetings. Webcasts of the presentations will be available on the Aclaris website for 30 days.
Aclaris Therapeutics (ACRS) reported a net loss of $18.2 million for Q2 2021, an increase from $11.6 million in Q2 2020. Total revenue reached $1.8 million, slightly down from $2.0 million a year earlier. R&D expenses rose to $7.9 million, driven by development of ATI-450 and ATI-2138. The company successfully secured $134.9 million in net proceeds from a public offering in June, allowing them to extend their cash runway through late 2024. Preliminary positive topline data for the Phase 2a trial of ATI-1777 in atopic dermatitis was also announced.
Aclaris Therapeutics, Inc. (NASDAQ: ACRS) announced that Dr. Neal Walker, President and CEO, will participate in a virtual panel at the William Blair Biotech Focus Conference on July 15, 2021, at 11:00 a.m. ET. The panel discussion will focus on 'Novel Targets for Autoimmune Diseases.' Management will also be available for virtual one-on-one meetings throughout the day. A live webcast can be accessed on Aclaris' website and will be archived for 30 days.
Aclaris is dedicated to developing innovative drug candidates for immuno-inflammatory diseases.
Aclaris Therapeutics, Inc. (Nasdaq: ACRS) announced a public offering of 7,042,254 shares at $17.75 each, with expected gross proceeds of approximately $125 million. The underwriters have a 30-day option to purchase an additional 1,056,338 shares at the public offering price. The offering is set to close around June 14, 2021, pending customary conditions. Jefferies LLC, SVB Leerink LLC, and Piper Sandler & Co. serve as joint book-running managers. A registration statement was filed with the SEC, and details can be found in the prospectus available on the SEC's website.
Aclaris Therapeutics, Inc. (Nasdaq: ACRS) announced plans for a public offering of $75 million in common stock, subject to market conditions. The company will offer up to an additional 15% of shares through a 30-day underwriter option. Jefferies LLC, SVB Leerink LLC, and Piper Sandler & Co. are leading the offering, with a registration statement already filed and effective as of May 20, 2021. The offering aims to generate funds for Aclaris' drug development pipeline targeting immuno-inflammatory diseases. However, there's no assurance of completion or specifics regarding the offering.
Aclaris Therapeutics, Inc. (NASDAQ: ACRS) announced positive preliminary results from its Phase 2a trial of ATI-1777, a topical JAK inhibitor for moderate to severe atopic dermatitis. The trial showed a statistically significant reduction in the modified Eczema Area and Severity Index (mEASI) score by 74.4% in the ATI-1777 group compared to 41.4% in the control. The drug was generally well tolerated with no serious adverse events. Aclaris plans to advance ATI-1777 to Phase 2b development following these findings. Management will discuss the results in a conference call today at 8 AM ET.
Aclaris Therapeutics, Inc. (NASDAQ: ACRS) announced that Dr. Neal Walker, President and CEO, will present at the Jefferies Virtual Healthcare Conference on June 1, 2021, at 1:00 p.m. ET. This presentation will provide an overview of the company's efforts in developing innovative drug candidates for immuno-inflammatory diseases. Aclaris' management will also be available for virtual one-on-one meetings throughout June 1st. The presentation can be viewed live on Aclaris' website, and the archive will be accessible for 30 days.
Aclaris Therapeutics (NASDAQ: ACRS) reported Q1 2021 results with a net loss of $28.8 million, up from $15.6 million in Q1 2020. Total revenue increased to $1.8 million from $1.4 million. The company holds $142.7 million in cash and equivalents, sufficient to fund operations through 2023. Aclaris is advancing its drug pipeline with a Phase 2b trial for ATI-450 in rheumatoid arthritis and two additional trials for hidradenitis suppurativa and psoriatic arthritis. Results from the Phase 2a trial of ATI-1777 for atopic dermatitis are expected in Q2 2021.
Aclaris Therapeutics (NASDAQ: ACRS) has completed enrollment in its Phase 2a clinical trial of ATI-1777, a topical JAK 1/3 inhibitor for treating moderate to severe atopic dermatitis. The trial, which is randomized and double-blind, aims to assess the drug's efficacy and safety. Results are anticipated by mid-2021. This milestone follows positive preliminary results from another trial of ATI-450 for rheumatoid arthritis. Aclaris continues to develop treatments targeting immuno-inflammatory diseases and aims to demonstrate ATI-1777's potential while minimizing systemic exposure.
Aclaris Therapeutics (NASDAQ: ACRS) announced promising preliminary topline data for ATI-450, an oral MK2 inhibitor, from its Phase 2a trial in moderate to severe rheumatoid arthritis. This investigational drug showed significant clinical activity with sustained reductions in DAS28-CRP scores and enhanced inflammatory biomarker suppression over 12 weeks. For Q4 2020, Aclaris reported a net loss of $13.2 million, a decrease from $18.6 million in Q4 2019, along with total revenues of $1.6 million. Following a public offering in January 2021, Aclaris secured $103.5 million to strengthen its balance sheet.